SWTXSpringWorks Therapeutics, Inc.

Nasdaq springworkstx.com


$ 38.54 $ 0.86 (2.28 %)    

Monday, 01-Jul-2024 15:59:59 EDT
QQQ $ 481.74 $ 2.81 (0.59 %)
DIA $ 391.56 $ 0.33 (0.08 %)
SPY $ 545.33 $ 1.12 (0.21 %)
TLT $ 90.13 $ -1.58 (-1.73 %)
GLD $ 215.59 $ 0.56 (0.26 %)
$ 38.53
$ 37.47
$ 0.00 x 0
$ 0.00 x 0
$ 37.13 - $ 39.23
$ 18.00 - $ 53.92
863,209
na
2.84B
$ 0.71
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-02-2024 03-31-2024 10-Q
2 02-27-2024 12-31-2023 10-K
3 11-02-2023 09-30-2023 10-Q
4 08-02-2023 06-30-2023 10-Q
5 05-03-2023 03-31-2023 10-Q
6 02-28-2023 12-31-2022 10-K
7 11-03-2022 09-30-2022 10-Q
8 08-04-2022 06-30-2022 10-Q
9 05-05-2022 03-31-2022 10-Q
10 02-24-2022 12-31-2021 10-K
11 11-04-2021 09-30-2021 10-Q
12 08-04-2021 06-30-2021 10-Q
13 05-05-2021 03-31-2021 10-Q
14 02-25-2021 12-31-2020 10-K
15 11-12-2020 09-30-2020 10-Q
16 08-12-2020 06-30-2020 10-Q
17 05-12-2020 03-31-2020 10-Q
18 03-12-2020 12-31-2019 10-K
19 11-12-2019 09-30-2019 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 springworks-therapeutics-has-completed-the-submission-of-a-new-drug-application-to-the-fda-for-mirdametinib-for-pediatric-and-adult-patients-with-neurofibromatosis-type-1--associated-plexiform-neurofibromas

In the second half of 2024, SpringWorks also plans to file a Marketing Authorization Application (MAA) with the European Medici...

Core News & Articles

- SEC Filing

Core News & Articles

- SEC Filing

Core News & Articles

- SEC Filing

Core News & Articles

- SEC Filing

 hc-wainwright--co-reiterates-buy-on-springworks-therapeutics-maintains-74-price-target

HC Wainwright & Co. analyst Robert Burns reiterates SpringWorks Therapeutics (NASDAQ:SWTX) with a Buy and maintains $74 ...

 hc-wainwright--co-reiterates-buy-on-springworks-therapeutics-maintains-74-price-target

HC Wainwright & Co. analyst Robert Burns reiterates SpringWorks Therapeutics (NASDAQ:SWTX) with a Buy and maintains $74 ...

 hc-wainwright--co-reiterates-buy-on-springworks-therapeutics-maintains-74-price-target

HC Wainwright & Co. analyst Robert Burns reiterates SpringWorks Therapeutics (NASDAQ:SWTX) with a Buy and maintains $74 ...

 springworks-therapeutics-q1-2024-gaap-eps-118-misses-116-estimate-sales-21006m-beat-12206m-estimate

SpringWorks Therapeutics (NASDAQ:SWTX) reported quarterly losses of $(1.18) per share which missed the analyst consensus estima...

 hc-wainwright--co-maintains-buy-on-springworks-therapeutics-raises-price-target-to-74

HC Wainwright & Co. analyst Robert Burns maintains SpringWorks Therapeutics (NASDAQ:SWTX) with a Buy and raises the pric...

 jp-morgan-maintains-overweight-on-springworks-therapeutics-raises-price-target-to-74

JP Morgan analyst Anupam Rama maintains SpringWorks Therapeutics (NASDAQ:SWTX) with a Overweight and raises the price target...

 barclays-maintains-overweight-on-springworks-therapeutics-raises-price-target-to-63

Barclays analyst Peter Lawson maintains SpringWorks Therapeutics (NASDAQ:SWTX) with a Overweight and raises the price target...

 wedbush-maintains-outperform-on-springworks-therapeutics-raises-price-target-to-70

Wedbush analyst David Nierengarten maintains SpringWorks Therapeutics (NASDAQ:SWTX) with a Outperform and raises the price t...

 barclays-maintains-overweight-on-springworks-therapeutics-raises-price-target-to-47

Barclays analyst Peter Lawson maintains SpringWorks Therapeutics (NASDAQ:SWTX) with a Overweight and raises the price target...